Treatment of rheumatoid arthritis using noble gas mixtures
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10022397-B2
Publication Date
2018-07-17
Expiration Date
Abstract
The invention disclosed provides means of inhibiting, ameliorating, and/or treatment of rheumatoid arthritis through the use of Noble gas containing mixtures. In one embodiment, the invention provides means of reducing inflammation and immune associated pathology through administration of Noble gas mixtures. In one specific embodiment, Xenon gas is administered to a patient in need at concentrations and frequencies sufficient to inhibit inflammatory and autoimmune processes. In another embodiment Noble gas mixtures are administered to reduce pain and provide symptomatic relieve to a patient suffering from rheumatoid arthritis. In another embodiment the use of Noble gas containing mixtures is disclosed as a means of reducing joint destruction through inhibition of matrix metalloprotease production and activity.
Core Innovation
The invention relates to treating rheumatoid arthritis and other T-cell–mediated autoimmune diseases by providing a noble gas composition that includes xenon and air or oxygen. The compositions comprise 25-30% xenon and 70-75% air or oxygen by total volume, and xenon administration is linked to immune modulation intended to reduce inflammation and inhibit rheumatoid arthritis pathology.
The disclosed concept provides immune modulation through induction of anti-inflammatory or immune modulatory processes in the patient. The immune effects are associated with T regulatory cell (Treg) phenotype and suppression of Th17 and other arthritogenic cells, and these changes are presented as contributing to reduced inflammation and pain in rheumatoid arthritis.
The disclosure further includes approaches for treatment monitoring using clinical scores and immunological biomarkers. Clinical monitoring is described using DAS28 and EULAR response criteria, and biomarker monitoring is described using markers such as CRP and inflammatory cytokines. The document also references a feasibility clinical trial design in DMARD-resistant rheumatoid arthritis with safety and efficacy endpoints.
Claims Coverage
The independent claims cover three therapeutic purposes while sharing the same noble gas composition constraint (25-30% xenon and 70-75% air or oxygen by total volume) and a patient-identification step. Across the independent claims, there are three main inventive feature sets aligned to treating rheumatoid arthritis symptoms, increasing sensitivity to an anti-cytokine biologic treatment, and inducing self-antigen specific tolerance in a rheumatoid arthritis patient intolerant to a self-antigen.
Treating rheumatoid arthritis with a xenon/air-or-oxygen noble gas composition
providing to said patient a noble gas composition comprising 25-30% xenon and 70-75% of air or oxygen by total volume of the noble gas composition in an amount sufficient to treat one or more symptoms of rheumatoid arthritis.
Increasing sensitivity to an anti-cytokine biologic treatment using a xenon/air-or-oxygen noble gas composition
providing to said patient a noble gas composition comprising 25-30% xenon and 70-75% of air or oxygen by total volume of the noble gas composition in an amount sufficient to increase sensitivity to said anti-cytokine biologic treatment.
Inducing self-antigen specific tolerance using a xenon/air-or-oxygen noble gas composition
providing to said patient a noble gas composition comprising 25-30% xenon and 70-75% of air or oxygen by total volume of the noble gas composition in an amount sufficient to induce tolerance to said self-antigen.
Across the independent claims, the claimed coverage centers on patient identification for rheumatoid arthritis and administration of a noble gas composition containing 25-30% xenon with 70-75% air or oxygen by total volume in an amount sufficient to achieve the claimed therapeutic purpose.
Stated Advantages
Reduced inflammation in rheumatoid arthritis.
Reduced pain in rheumatoid arthritis.
Inhibition of rheumatoid arthritis pathology.
Immune modulation, including anti-inflammatory/immune modulatory processes.
Potential increase in sensitivity to an anti-cytokine biologic treatment.
Induction of self-antigen specific tolerance in a rheumatoid arthritis patient intolerant to a self-antigen.
Documented Applications
Feasibility clinical trial design in DMARD-resistant rheumatoid arthritis with safety and efficacy endpoints, including clinical response measures and immunological biomarkers.
Interested in licensing this patent?